Raymond James upgraded shares of Heritage Oaks Bancorp (HEOP), a holding company for Heritage Oaks Bank (the Bank) from an “underperform” rating to a “market perform” rating.
Raymond James upgraded shares of Kendle International (KNDL), a global clinical research organization (CRO) that provides a range of Phase I to IV global clinical development services to the biopharmaceutical industry from an “underperform” rating to a “market perform” rating.
Global Hunter Securities upgraded shares of Quicksilver Resources Inc (KWK), an independent energy company, from a “neutral” rating to a “buy” rating. They now have a $17.50 price target on the stock, up previously from $17.00.
TD Newcrest upgraded shares of Louisiana-Pacific Co. (LPX), principally engaged in the manufacturing of building products, from a “reduce” rating to a “hold” rating.
Oppenheimer upgraded shares of Mindray Medical International Limited (MR) from a “perform” rating to an “outperform” rating. They now have a $32.00 price target on the stock.
Wunderlich upgraded shares of Rosetta Resources Inc. (ROSE) from a “hold” rating to a “buy” rating. They now have a $57.00 price target on the stock, up previously from $47.00.
HSBC upgraded shares of The Boston Beer Company Inc. (SAM) from an “underweight” rating to a “neutral” rating.
Goldman Sachs upgraded shares of Saks Inc (SKS) from a “sell” rating to a “neutral” rating. They now have a $12.00 price target on the stock.
Argus upgraded shares of Viacom Inc. (VIA.B) from a “hold” rating to a “buy” rating. They now have a $65.00 price target on the stock.
Leerink upgraded shares of Alkermes Inc. (ALKS) to an “outperform” rating, UBS AG upgraded shares of Credicorp Ltd. (BAP) to a “buy” rating.
McAdams Wright Ragen upgraded shares of Columbia Banking (COLB) to a “buy” rating. They now have a $22.00 price target on the stock.
Dahlman Rose upgraded shares of Calpine (CPN) from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock.
Wells Fargo & Co. upgraded shares of FirstEnergy Corp. (FE) from a “market perform” rating to an “outperform” rating.
Bank of America Merrill Lynch upgraded shares of Gamco Investors Inc. (GBL) from a “neutral” rating to a “buy” rating. They now have a $61.00 price target on the stock.
Lazard Capital upgraded shares of GTx Inc. (GTXI) from a “neutral” rating to a “buy” rating. They now have a $8.00 price target on the stock. GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that targets hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions.
SPECIAL DISCOUNT- SUBSCRIBE to CEOWORLD Magazine Digital Magazine & SAVE UP TO 80% OFF. Reaching more than 85,000 Chief Executive Officers and decision making executives who serve on the boards of leading companies. SUBSCRIBE NOW!!!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
